The Cytokine Storm Within

Clinical Vignette

A 38-year-old man with HIV infection diagnosed three years ago presents with six weeks of drenching night sweats, progressive fatigue, and a 20-pound weight loss. His antiretroviral therapy consists of bictegravir, emtricitabine, and tenofovir alafenamide, and his most recent HIV viral load was less than 20 copies/mL three months ago. His CD4 count at that time was 185 cells/μL. He denies cough, dysuria, diarrhea, or new skin lesions. He has no recent travel, sick contacts, or known tuberculosis exposure.

On examination he appears chronically ill and fatigued. Temperature is 38.2°C, heart rate 104 bpm, blood pressure 112/68 mmHg. Bilateral cervical, axillary, and inguinal lymph nodes are enlarged, firm, non-tender, and mobile, ranging from 1.5 to 3 cm. The spleen is palpable 4 cm below the left costal margin. No skin lesions, oral ulcers, or petechiae are present. The remainder of the examination is unremarkable.

Laboratory studies reveal hemoglobin 9.2 g/dL (MCV 86), white blood cell count 6,800/μL with a normal differential, platelet count 135,000/μL, albumin 2.4 g/dL, CRP 128 mg/L, and ESR 95 mm/hr. Creatinine, liver enzymes, and lactate dehydrogenase are within normal limits. Thick and thin blood smears are negative. Serum cryptococcal antigen is negative. Quantiferon-TB Gold is negative. Blood cultures show no growth at five days.

CT of the chest, abdomen, and pelvis demonstrates diffusely enlarged mediastinal, retroperitoneal, and mesenteric lymph nodes with a dominant 8.5 cm intensely enhancing retroperitoneal mass containing scattered calcifications. The spleen is enlarged at 16 cm. No pulmonary infiltrates or hepatic lesions are seen. An excisional biopsy of a right cervical lymph node is performed. Pathology reveals Castleman disease histology with expanded mantles, penetrating hyalinized vessels, and scattered plasmablasts in the interfollicular regions.

CT scan of the abdomen demonstrating a large enhancing retroperitoneal mass with intratumoral calcifications

CT scan of the abdomen demonstrating a large, enhancing retroperitoneal mass with intratumoral calcifications.

Question 1

What is the most likely diagnosis?

Select one option to submit your answer and view live poll results.


Question 2

Which of the following best characterizes the most likely etiologic agent?

Select one option to submit your answer and view live poll results.


Question 3

What is the most appropriate treatment?

Select one option to submit your answer and view live poll results.


Answer the question above to reveal the rationale.
Answer the question above to reveal the rationale.

References

Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. Journal of Clinical Oncology. 2011;29(18):2481-2486.

DOI: 10.1200/JCO.2010.34.1909

van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.

DOI: 10.1182/blood-2018-07-862334

Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124(24):3544-3552.

DOI: 10.1182/blood-2014-07-586800

Carbone A, De Paoli P, Gloghini A, Vaccher E. KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies. International Journal of Cancer. 2015;137(2):251-261.

DOI: 10.1002/ijc.28923

Nasir MW, Gao Y. Advances in KSHV research: molecular pathogenesis, immune evasion, and evolving therapeutic horizon. Journal of Medical Virology. 2025;97(11):e70695.

DOI: 10.1002/jmv.70695